Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug giant Teva Pharmaceutical Industries has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Teva and see what CAPS investors are saying about the stock right now.
Petach Tikva, Israel (1901)
CEO Dr. Jeremy Levin (since 2010)
Return on Equity (average, past 3 years)
$2.9 billion / $14.7 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 1,769 members who have rated Teva believe the stock will outperform the S&P 500 going forward.
Teva is a huge generic drug maker, with some outreach into the primary drug market. The company's balance sheet is strong, and the stock pays a reasonable dividend. With governments emphasizing cost controls for medical expense, Teva has a guaranteed market.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Teva may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Teva Is Ready to Rebound originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.